Shacey Petrovic - Insulet Chief Commercial Officer
| PODD Stock | USD 270.64 3.96 1.48% |
Executive
Ms. Shacey Petrovic was appointed President, Chief Executive Officer, Director effective January 1, 2019. Ms. Petrovic served as our Executive Vice President and President, Diabetes Products, and from February 2015 to February 2016, she served as our Chief Commercial Officer. From 2013 to 2015, Ms. Petrovic served as President and Chief Executive Officer of Clinical Innovations, LLC, a developer and manufacturer of medical devices and diagnostics for womens health. From 2000 to 2013, Ms. Petrovic served in a number of key roles at Hologic, Inc. and Cytyc Corporationrationration, which merged with Hologic in October 2007, including Vice President and General Manager of Hologics GYN Surgical Products division, as well as various sales and marketing leadership roles in the U.S. and Europe. Prior to joining Cytyc Corporationrationration, Ms. Petrovic served as a Pharmaceutical Sales Specialist at AstraZeneca since 2019.
| Age | 51 |
| Tenure | 6 years |
| Address | 100 Nagog Park, Acton, MA, United States, 01720 |
| Phone | 978 600 7000 |
| Web | https://www.insulet.com |
Latest Insider Transactions
Petrovic earned her BS in Biology from the University of Wisconsin.Insulet Management Efficiency
The company has return on total asset (ROA) of 0.068 % which means that it generated a profit of $0.068 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.4303 %, meaning that it created $0.4303 on every $100 dollars invested by stockholders. Insulet's management efficiency ratios could be used to measure how well Insulet manages its routine affairs as well as how well it operates its assets and liabilities. The current year's Return On Tangible Assets is expected to grow to 0.15. The current year's Return On Capital Employed is expected to grow to 0.13. At present, Insulet's Total Current Assets are projected to increase significantly based on the last few years of reporting. The current year's Non Current Assets Total is expected to grow to about 1.3 B, whereas Intangibles To Total Assets are forecasted to decline to 0.05.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Alon Yaari | InMode | N/A | |
| Nicholas Corcoran | TransMedics Group | 42 | |
| Scott Leinenweber | Abbott Laboratories | 52 | |
| Gary Sorsher | Edwards Lifesciences Corp | 59 | |
| Pankaj Tiwari | Penumbra | N/A | |
| Shruthi Narayan | Penumbra | N/A | |
| Leverne Marsh | DexCom Inc | N/A | |
| Arnold JD | Edwards Lifesciences Corp | 66 | |
| Matthew Dolan | DexCom Inc | 44 | |
| Susan Goodman | TransMedics Group | N/A | |
| Michael McBreen | Integra LifeSciences Holdings | 59 | |
| MPH MD | Inari Medical | N/A | |
| Daniel Lippis | Edwards Lifesciences Corp | 48 | |
| Stuart Silk | Stryker | N/A | |
| Srini Kaza | Align Technology | N/A | |
| Susan Krause | Integra LifeSciences Holdings | N/A | |
| Michael Dennison | InMode | N/A | |
| Sadie Stern | DexCom Inc | 50 | |
| Donald Abbey | DexCom Inc | 58 | |
| Angela Ahmad | Inari Medical | N/A | |
| Kevin Strange | Inari Medical | N/A | |
Management Performance
| Return On Equity | 0.43 | ||||
| Return On Asset | 0.068 |
Insulet Leadership Team
Elected by the shareholders, the Insulet's board of directors comprises two types of representatives: Insulet inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Insulet. The board's role is to monitor Insulet's management team and ensure that shareholders' interests are well served. Insulet's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Insulet's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Eric Benjamin, Senior Vice President R&D, New Product Development and Commercialization | ||
| Philip Hildale, Senior Care | ||
| Andrew Isaacson, Senior Development | ||
| Mark Field, Senior CTO | ||
| Prem Singh, Senior Operations | ||
| Laetitia Cousin, Quality Affairs | ||
| John JD, Senior Counsel | ||
| John Kapples, Senior Vice President General Counsel, Secretary | ||
| Wayde McMillan, CFO, Executive Vice President | ||
| Angela Wiczek, Senior Communications | ||
| Charles Alpuche, Senior Vice President Global Manufacturing and Operations | ||
| Lauren Budden, Chief VP | ||
| Michael Spears, Senior Vice President Quality, Regulatory, and Clinical Affairs | ||
| James Hollingshead, CEO President | ||
| Bret Christensen, Chief Commercial Officer | ||
| Ana Chadwick, CFO VP | ||
| June Lazaroff, Senior Relations | ||
| Deborah CPA, Vice Relations | ||
| Shacey Petrovic, Chief Commercial Officer | ||
| Trang Ly, Senior Officer |
Insulet Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Insulet a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.43 | ||||
| Return On Asset | 0.068 | ||||
| Profit Margin | 0.20 % | ||||
| Operating Margin | 0.16 % | ||||
| Current Valuation | 20.35 B | ||||
| Shares Outstanding | 70.23 M | ||||
| Shares Owned By Insiders | 0.75 % | ||||
| Shares Owned By Institutions | 99.25 % | ||||
| Number Of Shares Shorted | 2.44 M | ||||
| Price To Book | 16.43 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Insulet is a strong investment it is important to analyze Insulet's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Insulet's future performance. For an informed investment choice regarding Insulet Stock, refer to the following important reports:Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Insulet. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment. For information on how to trade Insulet Stock refer to our How to Trade Insulet Stock guide.You can also try the Technical Analysis module to check basic technical indicators and analysis based on most latest market data.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Insulet. If investors know Insulet will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Insulet listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.06) | Earnings Share 5.78 | Revenue Per Share | Quarterly Revenue Growth 0.172 | Return On Assets |
The market value of Insulet is measured differently than its book value, which is the value of Insulet that is recorded on the company's balance sheet. Investors also form their own opinion of Insulet's value that differs from its market value or its book value, called intrinsic value, which is Insulet's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Insulet's market value can be influenced by many factors that don't directly affect Insulet's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Insulet's value and its price as these two are different measures arrived at by different means. Investors typically determine if Insulet is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Insulet's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.